Risperidone 1 MG

DRUG4 trials

Sponsors

Centre for Addiction and Mental Health, University of Calgary, Medical University of Vienna

Conditions

AnhedoniaDepression - Major Depressive DisorderInvestigating the Importance of the Subjective Psychedelic ExperienceTreatment Resistant DepressionTreatment-resistant Depression

Phase 1

Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects

RecruitingNCT07490353

Medical University of ViennaAnhedonia, Depression - Major Depressive Disorder

Start: 2025-11-01End: 2028-05-31Target: 85Updated: 2026-03-24

Phase 2

Does Psilocybin Require Psychedelic Effects to Treat Depression?

CompletedNCT05710237

Centre for Addiction and Mental HealthTreatment-resistant Depression

Start: 2023-07-01End: 2026-04-14Updated: 2026-05-07

Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)

RecruitingNCT06512220

Centre for Addiction and Mental HealthTreatment Resistant Depression

Start: 2025-04-21End: 2027-09-30Target: 12Updated: 2025-05-04

Subjective Experience Following Psilocybin

RecruitingNCT06768944

University of CalgaryInvestigating the Importance of the Subjective Psychedelic Experience

Start: 2026-05-15End: 2028-01-01Target: 128Updated: 2026-05-22